Applying trial-derived treatment effects to real-world populations: how to estimate cost-effectiveness when modelling complex hazards
Ian Koblbauer, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford
General Research Seminars
Thursday, 08 September 2022, 2pm to 3pm
Hosted by HERC
Date and Time: Thursday 08 September 2022, 2:00 pm (UK BST)
To Join: This is a free event, which will be taking place online via Zoom. To register your interest in attending this talk please click HERE
Abstract: Generalisability of trial-based evidence to real-world target populations is important for decision making. In the context of independent aggregate time-to-event baseline and relative effects data, complex hazards can make modelling of data for use in economic evaluation challenging. Ian will present an overview of approaches for applying trial-derived relative treatment effects to external real-world baselines, and how they can impact cost-effectiveness estimates using an example cost-effectiveness analysis of Head and Neck Cancer treatments.
Biography: Ian is a Clarendon Scholar studying at the Centre for Statistics in Medicine and Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford. His DPhil is investigating the use of observational data alongside clinical trials to inform health economic evaluation, including methods to derive comparative effectiveness and other parameter estimates from routinely collected data for use in cost-effectiveness analysis. He has previously worked in consulting and research roles for the pharmaceutical industry and NHS.